According to Shanwaishan's announcement, Chongqing Tianwaitian Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration. The product is a single-use hemodialysis pipeline. The registration category is first-time registration, and the management category is Class III, which is valid until July 19, 2031. The acquisition of this product registration certificate is a milestone in the company's commercialization of R&D results. It will improve the company's product matrix and enhance competitiveness, but the actual sales situation of the product cannot be predicted.

According to Shanwaishan's announcement, Chongqing Tianwaitian Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, recently received the “People's Republic of China Medical Device Registration Certificate” issued by the State Drug Administration. The product is a single-use hemodialysis pipeline. The registration category is first-time registration, and the management category is Class III, which is valid until July 19, 2031. Obtaining this product registration certificate is a milestone in the company's commercialization of R&D results. It will improve the company's product matrix and enhance competitiveness, but the actual sales situation of the product cannot be predicted.